Black Diamond Therapeutics (BDTX) Projected to Post Quarterly Earnings on Thursday

Black Diamond Therapeutics (NASDAQ:BDTX) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect Black Diamond Therapeutics to post earnings of $0.10 per share and revenue of $23.33 million for the quarter.

Black Diamond Therapeutics (NASDAQ:BDTX) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03. On average, analysts expect Black Diamond Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Black Diamond Therapeutics Trading Down 6.2 %

NASDAQ BDTX opened at $1.67 on Tuesday. Black Diamond Therapeutics has a 12 month low of $1.20 and a 12 month high of $7.66. The stock has a market cap of $94.65 million, a price-to-earnings ratio of -1.26 and a beta of 2.63. The company’s 50 day moving average is $1.62 and its two-hundred day moving average is $2.19.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. HC Wainwright raised their price objective on shares of Black Diamond Therapeutics from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday, March 18th. Stifel Nicolaus lowered their price objective on Black Diamond Therapeutics from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, March 7th. Finally, Wedbush reiterated an “outperform” rating and set a $11.00 target price on shares of Black Diamond Therapeutics in a research report on Wednesday, March 19th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $14.60.

Insiders Place Their Bets

In other news, major shareholder Growth N. V. Biotech sold 5,784,292 shares of the firm’s stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $2.07, for a total transaction of $11,973,484.44. Following the completion of the transaction, the insider now owns 2,733,547 shares in the company, valued at $5,658,442.29. This trade represents a 67.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 8.87% of the company’s stock.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.